Market capitalization | $214.79m |
Enterprise Value | $138.28m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 419.03 |
P/S ratio (TTM) P/S ratio | 650.88 |
P/B ratio (TTM) P/B ratio | 1.47 |
Revenue growth (TTM) Revenue growth | -0.90% |
Revenue (TTM) Revenue | $330.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a ATAI Life Sciences N.V. forecast:
7 Analysts have issued a ATAI Life Sciences N.V. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.33 0.33 |
0%
0%
|
|
Gross Profit | -0.02 -0.02 |
88%
88%
|
|
EBITDA | -106 -106 |
18%
18%
|
EBIT (Operating Income) EBIT | -106 -106 |
18%
18%
|
Net Profit | -129 -129 |
92%
92%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.
Head office | Netherlands |
CEO | Florian Rao |
Employees | 83 |
Founded | 2018 |
Website | www.atai.life |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.